Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.53 |
| ▸ | PIM1 | P11309 | 4/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13776788 | 0.90 | USP30 (0.50) | USP30PIM1PIM2IRAK1PARP1 | |
| SCHEMBL13776786 | 0.86 | USP30 (0.49) | USP30PIM1PIM2IRAK1PARP1 | |
| SCHEMBL13764319 | 0.85 | CNR1 (0.47) | USP30PIM1PIM2PARP1JAK2 | |
| SCHEMBL13776791 | 0.85 | CHEK1 (0.49) | USP30PIM1PIM2IRAK1PARP1 | |
| SCHEMBL13776790 | 0.84 | USP30 (0.48) | USP30PIM1PIM2IRAK1PARP1 | |
| SCHEMBL21599063 | 0.77 | JAK3 (0.51) | USP30PIM1PIM2JAK2JAK3 | |
| SCHEMBL31227090 | 0.75 | USP30 (0.46) | USP30PIM1PIM2PARP1PIK3CD | |
| SCHEMBL31227754 | 0.74 | USP30 (0.48) | USP30PIM1PIM2PIK3CDANO1 | |
| SCHEMBL31227342 | 0.72 | PIK3CD (0.51) | USP30PIM1PIM2IRAK1JAK2 | |
| SCHEMBL2489770 | 0.72 | USP30 (0.52) | USP30PIM1PIM2PARP1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | CHEK1, CHEK2, CDKN1A | USP30 1066/4885PIM1 259/4885PIM2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.